Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Ocugen (NASDAQ:OCGN)

Ocugen shares fall, despite positive eye disorder trial

A trial of Ocugen's gene therapy for sight-robbing disease geographic atrophy (GA) showed efficacy – but still sparked a selloff in its shares.

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Ocugen (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN) on Thursday shared preliminary data from its phase 2 clinical trial for OCU410, a gene therapy targeting geographic atrophy. • Ocugen stock is taking a hit today. What’s weighing on OCGN shares? The stock’s decline comes as the broader market is experiencing gains, with major indices such as the S&P 500 up 0.64% and the Nasdaq gaining 1.07%. Ocugen’s Phase 2 Trial Shows 46% Lesion Reduction Preliminary results from the…

Ocugen sets sights on Phase III after GA gene therapy win

Ocugen's OCU410 controlled lesion growth 46% better than placebo in dAMD-related GA; the therapy will now progress to Phase III in the indication.The post Ocugen sets sights on Phase III after GA gene therapy win appeared first on Clinical Trials Arena.

Ocugen Reports Positive Preliminary 12-Month Phase 2 Data for OCU410 in GA

Ocugen announced positive preliminary 12-month results from its phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), a novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The interim analysis includes approximately 50% of patients evaluated to date and shows statistically significant reductions in GA lesion growth compared with untreated controls.  In the phase 2 ArMaDa study, …

Release - Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Channelchek

Open the article to view the coverage from channelchek.com

Q&A: Evolving approaches to geographic atrophy management

David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies.